Are you Dr. Goodman?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 71 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1221 Madison St
Seattle, WA 98104Phone+1 206-386-2323Fax+1 206-386-2729
Summary
- Dr. Gary Goodman, MD is a hematologist in Seattle, Washington. He is currently licensed to practice medicine in Washington and Idaho. He is affiliated with Swedish Cherry Hill Campus, St. Anne Hospital, and Providence Swedish Edmonds.
Education & Training
- University of Arizona College of Medicine-TucsonFellowship, Hematology and Medical Oncology, 1978 - 1981
- Oregon Health & Science University (OHSU Health)Residency, Internal Medicine, 1974 - 1977
- University of Illinois College of MedicineClass of 1974
Certifications & Licensure
- WA State Medical License 1981 - 2022
- ID State Medical License 1995 - 2005
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- Carotene and Retinol Efficacy Trial Start of enrollment: 1985 May 01
- Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
- Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsEffects of vitamin D supplementation on a deep learning-based mammographic evaluation in SWOG S0812.Julia E McGuinness, Garnet L Anderson, Simukayi Mutasa, Dawn L Hershman, Mary Beth Terry
JNCI Cancer Spectrum. 2024-07-01 - 1 citationsIdentification of genetically predicted DNA methylation markers associated with non-small cell lung cancer risk among 34,964 cases and 448,579 controls.Xiaoyu Zhao, Meiqi Yang, Jingyi Fan, Mei Wang, Yifan Wang
Cancer. 2024-03-15 - 1 citationsLung Cancer in Ever- and Never-Smokers: Findings from Multi-Population GWAS Studies.Yafang Li, Xiangjun Xiao, Jianrong Li, Younghun Han, Chao Cheng
Cancer Epidemiology, Biomarkers & Prevention. 2024-03-01
Grant Support
- The Carotene And Retinol Efficacy Trial (CARET)National Cancer Institute2000–2006
- Caret-Chlamydia Pneumonia And Risk Of Lung CancerNational Cancer Institute2001
- The Carotene And Retinol Efficacy TrialNational Cancer Institute1999
- Caret--Coordinating CenterNational Cancer Institute1997–1998
- Caret: The Seattle Study CenterNational Cancer Institute1995–1996
- CaretNational Cancer Institute1994
- Side Effects In Chemoprevention With Beta-Carotene And RetinalNational Cancer Institute1991–1993
- Side{ Effects In Chemoprevention With Eta-Carotene And RetinalNational Cancer Institute1988–1990
- Clinical Trial Using Monoclonal ImmunoconjugatesDivision Of Cancer Treatment1986–1989
- Chemoprevention Of Lung Cancer With RetinolNational Cancer Institute1986–1987
- Chemoprevention Of Lung Cancer With RetinolNational Cancer Institute1985
Professional Memberships
- Member